mta1 (Santa Cruz Biotechnology)
Structured Review
Mta1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 159 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mta1/MTA1+Antibody/pmc12704216-52-9-15
Average 93 stars, based on 159 article reviews
Images
Related Articles
other:Article Title: Nicotinic Acid-Mediated Modulation of Metastasis-Associated Protein 1 Methylation and Inflammation in Brain Arteriovenous Malformation. Article Snippet: We used the following antibodies for the experiments: Article Title: Leptin-Upregulated Metastasis-Associated Protein 1 Promotes Vasculogenic Mimicry in Breast Cancer Cells Article Snippet: Incubation:Article Title: Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Article Snippet: Objectives: Cisplatin-based chemotherapy represents the gold standard in the treatment of advanced bladder cancer (BC) both in the neoadjuvant and adjuvant setting.. Since novel immunooncologic agents are available for cisplatin-resistant or ineligible patients, biological markers for the prediction of cisplatin resistance become more important in treatment decisions.. Therefore, we aimed to assess the therapy predictive value of 8 promising tissue biomarkers with regard to cisplatin therapy. Article Title: Membranous CD44v6 is upregulated as an early event in colorectal cancer: Downregulation is associated with circulating tumor cells and poor prognosis Article Snippet: .. Sections were incubated at 4°C overnight with the following primary antibodies at the specified dilutions mCD44v6 (Bio-Rad MCA1730, dilution 1:100), Immunohistochemistry:Article Title: Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Article Snippet: Objectives: Cisplatin-based chemotherapy represents the gold standard in the treatment of advanced bladder cancer (BC) both in the neoadjuvant and adjuvant setting.. Since novel immunooncologic agents are available for cisplatin-resistant or ineligible patients, biological markers for the prediction of cisplatin resistance become more important in treatment decisions.. Therefore, we aimed to assess the therapy predictive value of 8 promising tissue biomarkers with regard to cisplatin therapy. Staining:Article Title: Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Article Snippet: Objectives: Cisplatin-based chemotherapy represents the gold standard in the treatment of advanced bladder cancer (BC) both in the neoadjuvant and adjuvant setting.. Since novel immunooncologic agents are available for cisplatin-resistant or ineligible patients, biological markers for the prediction of cisplatin resistance become more important in treatment decisions.. Therefore, we aimed to assess the therapy predictive value of 8 promising tissue biomarkers with regard to cisplatin therapy. |
